尿酸是1型糖尿病患者肾功能下降、心血管事件和死亡的独立危险因素
该研究在670例伴不同白蛋白尿水平的1型糖尿病患者中检测血浆尿酸,随访约5–6年,分析尿酸与eGFR下降≥30%、心血管事件及死亡的关系。结果显示尿酸每翻倍,上述结局风险均显著升高,且独立于传统危险因素,加入尿酸可改善风险预测。
要点
- 1型糖尿病患者尿酸升高与肾功能下降、心血管事件和死亡风险独立相关。
- 尿酸每翻倍,eGFR下降≥30%风险HR 3.18,心血管事件HR 2.25,死亡HR 2.58。
- 尿酸或可用于1型糖尿病患者的风险分层。
核心结论
- 在1型糖尿病患者中,较高尿酸水平与其他危险因素无关地关联肾功能下降、心血管事件和死亡风险升高。
- 结果提示尿酸在1型糖尿病风险分层中具有应用前景。
研究设计与样本
- 在670例伴正常白蛋白尿至大量白蛋白尿的1型糖尿病患者中测量血浆尿酸。
- 分析尿酸与eGFR下降≥30%、心血管事件和死亡的关系,并报告单变量和多变量关联。
- 风险比按尿酸水平每翻倍计算。
主要发现
- 尿酸每翻倍与eGFR下降≥30%(n=89)风险升高相关,校正后HR 3.18(IQR 1.71-5.93),P<0.001。
- 尿酸每翻倍与心血管事件(n=94)风险升高相关,校正后HR 2.25(IQR 1.20-4.21),P=0.011。
- 尿酸每翻倍与死亡(n=58)风险升高相关,校正后HR 2.58(IQR 1.12-5.90),P=0.025。
- 将尿酸加入含传统危险因素的校正模型后,eGFR下降≥30%的相对IDI改善12.6%(P<0.001),心血管事件改善6.5%(P=0.010),死亡改善11.8%(P=0.003)。
- 校正分析中尿酸每翻倍还与eGFR下降更陡(P<0.0026)及尿白蛋白/肌酐比值升高更陡(P<0.0027)相关。
临床怎么用
- 在1型糖尿病管理中可考虑检测尿酸,用于识别肾功能下降、心血管事件和死亡高风险患者。
- 尿酸可作为现有传统危险因素之外的风险分层补充指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have provided inconclusive results on the role of uric acid (UA) in risk prediction. Here we aimed to improve the power and precision of the predictive value of UA for the risk of decline in kidney function, cardiovascular events (CVEs), and mortality in patients with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Plasma UA was measured in 670 patients with T1D and various degrees of albuminuria, ranging from normoalbuminuria to macroalbuminuria. Associations of UA with an estimated glomerular filtration rate (eGFR) decline of ≥30%, CVEs, and mortality were analyzed. The median follow-up time was 5.3 years [interquartile range (IQR) 2.7-6.2 years] for a decline in eGFR of ≥30%, 5.8 years (2.5-6.4 years) for progression in albuminuria status, 5.1 years (4.7-5.6 years) for CVE, and 6.2 years (5.8-6.7 years) for mortality. Both univariable and multivariable associations of UA with relevant outcomes and variables were reported. Hazard ratios (HRs) were calculated per doubling of the UA level. RESULTS: A doubling in UA level was associated with a higher risk of decline in eGFR of ≥30% (n = 89) (HR 3.18 [IQR 1.71-5.93]; P < 0.001), CVE (n = 94) (HR 2.25 [IQR 1.20-4.21]; P = 0.011), and mortality (n = 58) (HR 2.58 [IQR 1.12-5.90]; P = 0.025) in adjusted analyses. Adding UA to the adjusted model including conventional risk factors improved the relative integrated discrimination index by 12.6% for a decline in eGFR of ≥30% (P < 0.001), 6.5% for CVE (P = 0.010), and 11.8% (P = 0.003) for mortality. A doubling in UA level was also associated with a steeper decline in eGFR (P < 0.0026) and a steeper increase in urine albumin-to-creatinine ratio (P < 0.0027) in adjusted analysis. CONCLUSIONS: In individuals with T1D, a higher UA level is associated with a higher risk of decline in kidney function, CVE, and mortality, independently of other risk factors. Our results suggest that UA has a promising role in risk stratification among individuals with T1D.
引用
- Pilemann-Lyberg S, Hansen TW, Tofte N, et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care. 2019. PMID: 30885950. doi:10.2337/dc18-2173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。